1. Prognostic Value of the Delivery Dialysis Dose on Twice-Weekly Hemodialysis Patients
Fan et al. Am J Nephrol 2017;45:   (DOI: / )
Table 1. Baseline demographic characteristics of twice-weekly dialysis patients

2. Prognostic Value of the Delivery Dialysis Dose on Twice-Weekly Hemodialysis Patients
Fan et al. Am J Nephrol 2017;45:   (DOI: / )
Fig. 1. Flow chart of study participants for the randomized controlled trial to evaluate the prognosis as well as to determine the impact of dialysis dose and other risk factors for twice-weekly HD patients.

3. Prognostic Value of the Delivery Dialysis Dose on Twice-Weekly Hemodialysis Patients
Fan et al. Am J Nephrol 2017;45:   (DOI: / )
Table 2. Comparison of clinical parameters between high- and standard-dose groups

4. Prognostic Value of the Delivery Dialysis Dose on Twice-Weekly Hemodialysis Patients
Fan et al. Am J Nephrol 2017;45:   (DOI: / )
Table 3. ORs for dialysis prescription contribution to increasing of Kt/V

5. Prognostic Value of the Delivery Dialysis Dose on Twice-Weekly Hemodialysis Patients
Fan et al. Am J Nephrol 2017;45:   (DOI: / )
Fig. 2. Changes in spKt/V (a), eKt/V (b), and stdKt/V (c) between high- and standard-dose groups throughout different study phases. Changes of dialysis length per session (d), blood flow (e), dialyzer surface area (f) between high- and standard-dose group throughout different study phases. **p < and * p < 0.01 in Kt/V comparison between 2 groups.

6. Prognostic Value of the Delivery Dialysis Dose on Twice-Weekly Hemodialysis Patients
Fan et al. Am J Nephrol 2017;45:   (DOI: / )
Table 4. All-cause mortality and MACEs between high- and standard-dose groups

7. Prognostic Value of the Delivery Dialysis Dose on Twice-Weekly Hemodialysis Patients
Fan et al. Am J Nephrol 2017;45:   (DOI: / )
Fig. 3. Kaplan-Meier analysis and log-rank test for twice-weekly HD patients. a Estimates of cumulative survival among high-dose group with an spKt/V ≥1.70 (solid line) and standard-dose group with 1.20 ≤ spKt/V < 1.70 (broken line) without significant difference (χ2 = 0.23, p = 0.631). b Estimates of MACE-free survival among high-dose group (solid line) better than standard-dose group (broken line) with statistical difference (χ2 = 4.77, p = 0.029).